GP CCE Cases · womens-health
Perimenopausal HRT decision — CCE clinical encounter
CCE-style clinical encounter: a 51-year-old with disabling flushes, obesity and a family history of breast cancer wants 'something that works'. The candidate must diagnose perimenopause clinically, quantify WHI-era risks honestly, prescribe transdermal-first with micronised progesterone, and set the review rhythm.
On this page
Study tools
Target exams
RACGP CCEFRACGP oralsCFPC SOOs
Prompt
A 51-year-old office manager attends exhausted. Night sweats wake her three to four times nightly; hot flushes disrupt client meetings; periods now arrive every five weeks and heavy. BMI 33 kg/m²; BP 132/84; mother diagnosed with breast cancer at 71; a colleague at work 'ended up in hospital from HRT' — she has read that hormone therapy causes breast cancer and clots, but says 'I cannot keep living like this'.
Objectives
- Make the clinical diagnosis of perimenopause without laboratory tests, and explain why no test is needed. [3]
- Elicit the symptom inventory (vasomotor, sleep, mood, cycle change) and its duration expectations. [15]
- Reframe the WHI narrative with absolute numbers appropriate to her age. [1] [17]
- Prescribe a regimen shaped by route and progestogen evidence for her risk profile. [3] [7] [10]
- Agree review structure, safety-net bleeding rules, and contraception needs. [3]
References6ShowHide
- [1]Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013.PMID 24084921
- [3]Sarri G, Davies M, Lumsden MA et al. Diagnosis and management of menopause: summary of NICE guidance. BMJ, 2015.PMID 26563259
- [7]Rovinski D, Ramos RB, Fighera TM et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thrombosis research, 2018.PMID 29936403
- [10]Fournier A, Berrino F, Clavel-Chapelon F Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast cancer research and treatment, 2008.PMID 17333341
- [15]Avis NE, Crawford SL, Greendale G et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA internal medicine, 2015.PMID 25686030
- [17]The North American Menopause Society The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022.PMID 35797481